AstraZeneca Buys Fusion Pharma for Up to $2.4B
After a shift in focus to develop Covid-19 vaccines, the Fusion deal marks a return to CEO Pascal Soriot’s focus on oncology.
Enter the email associated with your account and we'll send you a link to reset your password.